Menu
← Oncology Approval Tracker
FDA DECISION ·
Datroway
datopotamab deruxtecan-dlnk · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic TNBC who are ineligible for PD-1 or PD-L1 inhibitor therapy.
LAMPGEN ANALYSIS
Why it matters
TROPION-Breast02 studied a TROP2 ADC in previously untreated advanced disease in people who could not receive checkpoint inhibitor therapy. Keep the trial line and labeled population clear.
What research teams should watch
Record checkpoint inhibitor ineligibility and the pretreatment history. Include pulmonary symptom escalation and oral toxicity surveillance when discussing monitoring.
PRIMARY RECORDS